pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today anno…
American Academy Of Ophthalmology Responds To Genentech Rebate Program For Lucentis Use
Genentech (Hoffman – La Roche) manufactures two critically important pharmaceuticals, Lucentis and Avastin, which are both used for treatment of several common eye diseases – including age-related macular degeneration (AMD).
Uncontrolled Hypertension, Chronic Kidney Disease May Increase Retinopathy Risk
High blood pressure and chronic kidney disease are associated with a higher incidence of retinopathy in subjects who are not diabetic, a study found.
With Cataracts, Misinformation Seems To Abound
When medical experts talk about prevalence, they’re usually referring to how common a particular disease might be. But in the case of cataracts, they might just as well be talking about how common it is to uncover misinformation and misunderstanding ab…
PSivida Corp (PSDV) Says FDA Can’t Clear Diabetic Macular Edema Drug; Seeks Further Data On Alimera Sciences (ALIM)’ Iluvien
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today anno…
American Academy Of Ophthalmology Responds To Genentech Rebate Program For Lucentis Use
Genentech (Hoffman – La Roche) manufactures two critically important pharmaceuticals, Lucentis and Avastin, which are both used for treatment of several common eye diseases – including age-related macular degeneration (AMD).